website creation software

WHO WE ARE

The leaders of SIGLA SCIENCES have decades of experience in pharma, biotech, and diagnostics, and have worked on dozens of product launches in oncology, specialty, and rare disease areas. Our team has also helped companies shape cross-portfolio marketing strategies, build commercial revenue forecasts, develop in-depth policy impact assessments, and create compelling payer value propositions for specialty products.

Many consultants offer advice, but few can transform it into executable strategies forged by real-world leadership experience. We bridge that gap, translating high-level strategies into messaging, creative tactics, digital plans, and operational roadmaps to win in the market—all at a fraction of typical agency costs through our lean, distributed model. We understand that the strategies and tactics that previously led to blockbuster products are insufficient to guarantee access, market reach, and a strong value proposition in today's more challenging and sophisticated payer and provider landscape.

Our hands-on leadership team has walked in your shoes, having held client-side roles. We understand the importance of managing resources judiciously, delivering high-quality results on time, and fostering internal alignment. 

OUR EXECUTIVE TEAM

Jennifer Hinkel, MSc

President & Founder 

Niesha Griffith, MS, RPh, FASHP 

Chief Clinical & Pharmacy Officer 

Cory Kidd, PhD

Chief Digital & Patient Engagement Officer 

Devon Edwards, JD

Head, Health & Legal Strategy 

Our leadership team has previously worked in the life sciences industry ranging from digital health startups and policy organizations to precision medicine, NCI-designated cancer centers, and big pharma. Our CVs include the following past employers: Genentech, The James Cancer Center at The Ohio State University, City of Hope, National Comprehensive Cancer Network, Roche Pharma UK, Caris Life Sciences, Catalia Health, Morrison & Foerster LLP, the Association of State and Territorial Health Officials, and NASA. Our degrees are from MIT, Georgia Tech, the University of Texas, Princeton, The University of Oxford, the London School of Economics, West Virginia University, and The Ohio State University. Our team of consultants, creatives, and analysts include alumni of McKinsey, Bristol Myers Squibb, Accenture, Ferring Pharmaceuticals, J&J, and the University of Cambridge.

Read more from our bios below:

Jennifer Hinkel, MSc
President & Founder, Sigla Sciences

Jennifer Hinkel is an oncology market access and health economics leader with experience in consulting, global pharma and biotech, health policy, and health care startups. She has held management and executive roles at companies including National Comprehensive Cancer Network, Roche UK, Roche Argentina, Genentech, and Caris Life Sciences.

Previously, she was a Senior Partner at McGivney Global Advisors, where she built an oncology-focused consulting practice specializing in market access and HEOR topics. Ms. Hinkel held pricing, distribution, oncology marketing, and hospital sales roles at Roche and Genentech in the US, Latin America, and Europe. She also led financial impact assessment for the Affordable Care Act and Medicare reimbursement in Genentech's Industry Analytics group, for which she received the Genentech ACE Award. Prior to joining the biopharmaceutical industry, Ms. Hinkel held roles at National Comprehensive Cancer Network (NCCN), the Association for State and Territorial Health Officials (ASTHO), and as a researcher for a member of the United Kingdom House of Lords. She also sits on the board of several early-stage technology and science companies.

Ms. Hinkel holds degrees from the Georgia Institute of Technology (BS International Affairs) and the London School of Economics (MSc International Health Policy), and is DPhil candidate in Evidence Based Health Care at the University of Oxford. She has lectured in Health Systems and Health Economics at Penn State University and Arcadia University, holds patents in health care technology, and has published numerous articles and abstracts related to market access and oncology health services research. As a survivor of Stage III Hodgkin Lymphoma, Ms. Hinkel has a special interest in oncology innovation as a cancer survivor. To support the broader survivor and oncology community, Ms. Hinkel founded Resilience Racing, the first all-cancer-survivor sailing team, and also launched the 40 Under 40 in Cancer annual awards program.


Niesha Griffith, MS, RPh, FASHP
Chief Clinical & Pharmacy Officer


Niesha Griffith is a national leader in hospital, pharmacy, and revenue operations in health care. She has held leadership roles at The James Cancer Center at The Ohio State University including leading outpatient oncology and pharmacy as The James was the highest volume cancer center in the United States. She has been the Cancer Center Director at West Virginia University, including a network-wide implementation of electronic ordering and EHR across oncology. Niesha also served as an interim Director of Pharmacy at City of Hope, helping revamp their revenue cycle management processes to significantly improve financial sustainability. Niesha has also held executive roles at Caris Life Sciences as a VP of Strategic Collaborations and as an Advisory Partner at McGivney Global Advisors.


Beyond these roles, Niesha has been known as a leading consultant to executive teams in the life sciences industry, particularly with regards to helping launch oncology products with operational success at the cancer center level. She was one of the founding leaders of the Pharmacy Directors group of the National Comprehensive Cancer Network while at The James and led the creation of the NCCN Chemotherapy Order Templates product which is now integrated into multiple electronic ordering and EHR systems for oncology. Further she was instrumental in the launch and operation of ICLIO, the Institute for Clincal Leadership in ImmunoOncology, which in partnership with ACCC was a critical success factor in bringing IO products to the clinic when this was a new treatment paradigm. Niesha is also a founder of HOPA, the Hematology and Oncology Pharmacy Association, and of ATOPP, the Advanced Topics for Oncology Pharmacy Professionals Summit.


EMAIL: info at siglasciences.com